Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease

Inclusion Criteria:

1. Be able to provide written informed consent

2. Have a diagnosis of PD with evidence of stable disease as determined by theinvestigator

3. Patient must have palpable penile plaque

4. Penile curvature deformity of >30° to <90°

5. Agree to comply with all study related tests/procedures.

6. Prior intralesional platelet rich plasma treatment within the past 18 months anddesire secondary treatment of penile curvature

Exclusion Criteria:

1. Previous penile surgery of any kind (except circumcision and condyloma removal),such as penile lengthening, penile cancer surgery, penile plication, grafting,penile prosthesis.

2. Previous intralesional injection therapy with CCH for PD within six months. Patientswith failed therapy greater than six months ago may be included.

3. Previous history of priapism or penile fracture

4. PD characterized by a ventral plaque

5. Severe erectile dysfunction as characterized with an IIEF score ≤ 12

6. Hour-glass deformity

7. Unwilling to participate

8. Medically unfit for sexual intercourse as deemed by the principal investigator

9. Patients scheduled to undergo an elective medical procedure during the investigationtimeframe that will interfere with autologous PRP injection therapy.

10. Have a serious comorbid illness/condition/behavior that, in the opinion of theinvestigator, may compromise the safety or compliance of the subject or precludesuccessful completion of the study.